Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Prospectively validated biomarker signature for personalized radiooncology: Results of the DKTK-ROG HNprädBio biomarker trial for primary RCT of HNSCC
Presenter Annett Linge 🇩🇪
The OncoAlert Network 🚨
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Geographic accessibility of proton therapy services in Europe: current status and opportunities for enhancement Presenter Dominik Wawrzuta 🇵🇱
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Mean dose rate-dependent skin sparing by FLASH-RT through suppressing the lysosomal membrane permeabilization-NLRP3 inflammasome axis in macrophages
Presented by Chen Wang 🇨🇳
#RadOnc ☢️
@estroradiotherapy.bsky.social
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Omission of elective nodal irradiation in HNSCC: long-term results and patient-level pooled analysis from 2 prospective trials (INRT-AIR & DARTBOARD)
Presenter Sympascho Young 🇺🇸
Day THREE of #ESTRO26 Coverage by OncoAlert 🚨
Moderately fractionated prostate radiotherapy with a focal boost: acute and preliminary late side effects from the phase 3 PIVOTALboost trial Presented by Isabel Syndikus 🇬🇧
#RadOnc ☢️
@estroradiotherapy.bsky.social
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Interim analysis of the EORTC ESTRO E2-Radiate 2011-RP ReCare cohort to assess adequacy of patient selection: Early death and adverse events after high-dose re-irradiation
Presented by Nicolaus Andratschke 🇨🇭
#RadOnc ☢️
@estroradiotherapy.bsky.social
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Agreement between patient and physician-reported symptoms during radiotherapy for prostate cancer in the HYPO-RT-PC trial Presented by Ulrika Rönningås 🇸🇪
#RadOnc ☢️ #ProstateCancer
@estroradiotherapy.bsky.social
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II)
www.thelancet.com/journals/lan...
FASTRACK II, the first phase 2 trial of stereotactic ablative body radiotherapy☢️ in #KidneyCancer #ESTRO26
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Early regression index-guided dose escalation in locally advanced rectal cancer: long term results of the prospective THUNDER-2 trial Presented by Giuditta Chiloiro 🇮🇹
#RadOnc ☢️
@estroradiotherapy.bsky.social
Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Best Physics Paper: Benchmarking synthetic computed tomography for radiotherapy from head to abdomen: SynthRAD2025 Grand Challenge report Presented by Matteo Maspero 🇳🇱
#RadOnc ☢️
